Eupraxia Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

James Helliwell

Chief Executive Officer (CEO)

US$517.3k

Compensación total

Porcentaje del salario del CEO	70.2%
Permanencia del CEO	12yrs
Participación del CEO	1.9%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	11.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de James Helliwell en comparación con los beneficios de Eupraxia Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$517k	US$363k	-US$28m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$24m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$953k	US$325k	-US$18m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	US$1m	US$297k	-US$19m

Compensación vs. Mercado: La compensación total de James($USD952.75K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD174.90K).

Compensación vs. Ingresos: La compensación de James ha sido consistente con los resultados de la empresa en el último año.

CEO

James Helliwell (50 yo)

12yrs

Permanencia

US$517,299

Compensación

Dr. James A. Helliwell, M.D., FRCPC serves as the Chief Executive Officer since July 2012 at Eupraxia Pharmaceuticals Inc. and served as its President until May 3, 2021. Dr. Helliwell serves as a Clinical...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Helliwell	CEO & Director	12yrs	US$517.30k	1.89% $ 2.3m
Bruce Cousins	President & CFO	3.2yrs	US$368.72k	0.32% $ 395.4k
Amanda Malone	Chief Scientific Officer & COO	11.8yrs	US$368.72k	0.13% $ 160.3k
Paul Brennan	Chief Business Officer	1.7yrs	US$343.12k	0.076% $ 94.1k
Mark Kowalski	Chief Medical Officer	1.2yrs	US$1.15m	0.022% $ 27.7k

3.2yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EPRX se considera experimentado (2.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Helliwell	CEO & Director	12yrs	US$517.30k	1.89% $ 2.3m
Simon Pimstone	Independent Chairman	11.5yrs	US$42.23k	0.024% $ 29.8k
Richard Glickman	Independent Director	3.3yrs	US$29.86k	0.039% $ 48.2k
Paul Geyer	Independent Director	11.5yrs	US$23.56k	0.96% $ 1.2m
John Montalbano	Independent Director	11.5yrs	US$29.86k	3.4% $ 4.2m
Michael Wilmink	Independent Director	11.5yrs	US$23.56k	0.63% $ 771.5k

11.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de EPRX son experimentados ( 11.3 años antigüedad media).

Eupraxia Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently bought CA$52k worth of stock

Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Eupraxia Pharmaceuticals Inc. Appoints Mark Kowalski as Chief Medical Officer

Eupraxia Pharmaceuticals Appoints Paul Brennan to Chief Business Officer

Independent Director recently bought CA$122k worth of stock

Recent updates

Independent Director recently bought CA$52k worth of stock

Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial

New minor risk - Market cap size

Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Price target decreased by 7.4% to CA$15.75

Eupraxia Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of CAD 30 million.

Eupraxia Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of CAD 30 million.

Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR

Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee

Price target increased by 12% to CA$16.50

Eupraxia Pharmaceuticals Inc. Announces Positive Clinical Data in EP-104GI RESOLVE Trial

Eupraxia Pharmaceuticals Inc. Announces Updates for Its Two Clinical Programs, EP-104IAR and EP-104GI

New minor risk - Market cap size

Eupraxia Pharmaceuticals Inc. Announces Initiation of Second Cohort in Phase 1B/2A Clinical Trial in Eosinophilic Esophagitis

Price target decreased by 20% to CA$14.75

Eupraxia Pharmaceuticals Inc. announced that it expects to receive CAD 21.999999 million in funding

New minor risk - Shareholder dilution

Eupraxia Pharmaceuticals Reports Positive Topline Data in Its Phase 2B Osteoarthritis Trial with Ep-104IAR

Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for Ep-104Iar in Treatment of Osteoarthritis

Eupraxia Pharmaceuticals Inc. Doses First Patient in Phase 1B/2A Eosinophilic Esophagitis Trial

Eupraxia Pharmaceuticals Inc. Appoints Mark Kowalski as Chief Medical Officer

Price target increased to CA$8.35

Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

Eupraxia Pharmaceuticals Appoints Paul Brennan to Chief Business Officer

Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR

Independent Director recently bought CA$122k worth of stock

Price target decreased to CA$6.50

Independent Director recently bought CA$427k worth of stock

Independent Director recently bought CA$427k worth of stock

Eupraxia Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 13.09335 million.

Independent Director recently bought CA$500k worth of stock

Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 02, 2022

Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 02, 2022

Independent Director recently bought CA$78k worth of stock

Eupraxia Pharmaceuticals Inc. Provides Update on Its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR

Eupraxia Pharmaceuticals Inc. Commences Patient Screening for its Phase 2 Trial for Osteoarthritis Drug Candidate Ep-104IAR

CEO & Director recently bought CA$73k worth of stock

Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of Ep-104Iar in Osteoarthritis of the Knee

Director recently bought CA$200k worth of stock

Eupraxia Pharmaceuticals Inc. has completed an IPO in the amount of CAD 41 million.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad